(NYSE:OPK) shares saw heavy trading volume with 18,771K shares changing hands in the last trading session. Volume was up 274.63% over the stocks average daily volume.
Short traders are more bullish on shares of Opko Health Inc lately if you take note of the downtick in short interest. The stock saw a fall in short interest between September 29, 2017 and October 13, 2017 of -1.85%. Short interest fell 1,345,161 over that period. With short interest at 71,351,349 and short average daily volume at 3,733,314, the short-interest ratio is 19.0 and the short interest percentage is 0.13% as of October 13.
Opko Health Inc (NYSE:OPK) has been the object of insider buying activity recently. Phillip Md Et Al Frost, CEO reported the purchase of 15,000 shares of (OPK). The shares were bought on September 19th for an average price of $6.00. The CEO now owns $2,370,000 of the stock according to the SEC filing. Phillip Md Et Al Frost, CEO acquired $240,000 worth of shares at an average price of $6.00 on Mon the 18th. That brings the CEO’s holdings to $2,280,000 as reported to the SEC.
Sr. Vice President, CFO Adam Logal acquired 1,500 shares at an average price of $6.03 on September 15th. That brings Logal’s holdings to $981,642 as recorded in a recent Form 4 SEC filing.
A few notable investment firms have updated their holdings. Dimensional Fund Advisors Lp expanded its investment by buying 2,241,103 shares an increase of 127.2% in the quarter. Dimensional Fund Advisors Lp controls 4,003,643 shares worth $27,466,000. The value of the position overall is up by 136.8%. Ubs Asset Management Americas Inc bolstered its holdings by buying 4,537 shares an increase of 2,548.9% from 06/30/2017 to 09/30/2017. Ubs Asset Management Americas Inc now holds 4,715 shares valued at $32,345,000. The total value of its holdings increased 2,662.2%.
As of the end of the quarter Baird Financial Group, Inc. had sold a total of 8,737 shares trimming its holdings by 15.0%. The value of the investment in OPK decreased from $383,000 to $340,000 decreasing 11.2% quarter to quarter. Raymond James & Associates reduced its position by shedding 79,217 shares a decrease of 24.5% as of 09/30/2017. Raymond James & Associates claims 243,789 shares with a value of $1,672,000. The total value of its holdings decreased 21.3%.
Equity analyst Cantor Fitzgerald updated coverage of OPK with a rating of “Buy” and projecting a price target of $20.00. On October 12 analysts at Cantor Fitzgerald issued a report on OPK and giving a rating of “Buy” and price target of $20.00.
On September 25 Ladenburg Thalmann Financial Services held the stock rating at “Buy” targeting a price of $16.00.
On August 17, 2017 Cantor Fitzgerald released a research note on OPK setting a rating of “Overweight”. August 10 investment analysts at Jefferies Group LLC kept the stock rating at “Hold” projecting a price of $6.50.
In the market the company is trading up since yesterday’s close of 4.61. The P/E ratio is currently N/A and the market cap is 2.64B. In the latest earnings report the EPS was $-0.19 with 559.41M shares presently outstanding.
OPKO Health, Inc., launched on November 18, 1991, is a diversified healthcare company. The Business’s segments include Pharmaceutical, Diagnostics and Corporate. The pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations..